Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL683556 | 0.91 | ACE (0.67) | ACELMNA | |
| SCHEMBL11065988 | 0.91 | ACE (0.67) | ACELMNA | |
| SCHEMBL10940835 | 0.87 | ACE (0.60) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL11194036 | 0.86 | ACE (0.59) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL10940950 | 0.83 | ACE (0.56) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL10968292 | 0.83 | ACE (0.64) | ACELMNAFFAR2ALDH1A1POLB | |
| SCHEMBL11062257 | 0.82 | ACE (0.55) | ACELMNAFFAR2HTT | |
| Rentiapril SCHEMBL323403 | 0.81 | ACE (1.00) | ACELMNAFFAR2ALDH1A1POLB | |
| Rentiapril SCHEMBL30422754 | 0.81 | ACE (1.00) | ACELMNAFFAR2ALDH1A1POLB | |
| Rentiapril SCHEMBL294980 | 0.81 | ACE (1.00) | ACELMNAFFAR2ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | ACE 4514/4885LMNA 3688/4885FFAR2 1345/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | ACE 6/4885LMNA 2155/4885FFAR2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.